Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
· seekingalpha.com
Spruce Biosciences is preparing a BLA submission in Q4, with FDA feedback suggesting acceptance of CSF HS-NRE as a surrogate endpoint. See why SPRB stock is a Buy.
Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamenta...